Drug news
Zonegran shows potential for partial Epilepsy in paediatric patients
Preliminary results from a new Phase III study of Zonegran (zonisamide) from Eisai, shows that it is more effective than placebo and well tolerated in paediatric patients with partial-onset seizures treated with one or two other anti-epileptic drugs. The data, presented at the 2011 International Epilepsy Congress, showed that significantly more patients responded positively to treatment with Zonegran (50.5%) versus treatment with placebo (31.0%).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins